The patent (US10154980B2) covers compositions containing EPA and DHA from any sources (the patent file lists plants, algae, fish, squid, and more) and lycopene. It also covers compositions with added carnosic acid and lutein.
“This patent is a milestone in Lycored’s plan program for developing innovative solutions for brain health, and we are excited to implement this new patent into our already extensive portfolio,” said Dr Karin Hermoni, PhD, head of science & nutrition at Lycored in an emailed statement.
The basis of the patent was a study the company funded, published in NeuroMolecular Medicine in 2017. In the paper, researchers from the Soroka University Medical Center and Ben-Gurion University of the Negev in Israel posited that an omega-3 and lycopene composition may inhibit inflammatory markers by suppressing anti-inflammatory mediators or the secretion of anti-inflammatory mediators from macrophages at a given site.
“This patent is just another example of Lycored’s commitment to overall wellness and, more specifically, it serves as a building block for the company as it continues to build its overall brain health program,” Dr Hermoni added.
“Omega-3s are commonly used for a wide array of health functions, and this is why Lycored decided to explore this vital category and to support the current market need for a synergistic combination for the use of omega-3.”
“Lycored is currently in the process of developing a new formulation that directly addresses the components of this new patent, which would enhance the use of existing omega-3 products and benefits to inflammatory markers that support overall brain health,” she added.